Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer

A method of treating cancer in a subject, comprising:

• (a) administering one or more formulations of tagged proteins to a subject in need of treatment, wherein the tagged proteins bind a cancer cell in the subject, and
• (b) administering one or more therapeutically-effective populations of AT-CAR-expressing effector cells to the subject, wherein the AT-CAR comprises a tag-binding domain, a transmembrane domain, and a T cell activation domain, where the T cell activation domain consists of one or more of the cytoplasmic region of OX40, the cytoplasmic region of HVEM, and FcRε, where the T cell activation domain does not comprise CD3ζ, and wherein the AT-CAR-expressing effector cells bind the tagged proteins and induce cancer cell death, thereby treating cancer in a subject.

A method of treating cancer in a subject, comprising:

• (a) administering at least two formulations of tagged proteins to a subject in need of treatment, wherein the tagged proteins bind a cancer cell in the subject, and
• (b) administering at least two therapeutically-effective populations of AT-CAR-expressing effector cells to the subject, wherein the AT-CAR comprises a tag-binding domain, a transmembrane domain, and a T cell activation domain, where the T cell activation domain consists of one or more of the cytoplasmic region of OX40, the cytoplasmic region of HVEM, and FcRε, where the T cell activation domain does not comprise CD3ζ, and wherein the AT-CAR-expressing effector cells bind the tagged proteins and induce cancer cell death, thereby treating cancer in a subject.